Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12127825 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL1854664 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL6387164 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL1855781 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL15174081 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL15174509 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL1341663 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL15174483 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL22854103 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL2405667 | 1.00 | CYP2D6 (0.52) | CYP2D6SPHK1SPHK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| EP-2822548-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | University Of Virginia Patent Foundation (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013119946-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1203767-B1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER LAMBERT CO (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5693657-A | USEFUL FOR TREATING HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, SGPL1 | CYP2D6 3912/4885SPHK1 1/4885SPHK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.